IA
ARQT icon

IFP Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

IFP Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8K Sell
183
-111
-38% -$2.59K ﹤0.01% 3822
2026
Q1 		$6.93K Sell
294
-7
-2% -$179 ﹤0.01% 3349
2025
Q4 		$8.74K Buy
301
+110
+58% +$2.82K ﹤0.01% 3132
2025
Q3 		$3.6K Buy
191
+4
+2% +$63 ﹤0.01% 3435
2025
Q2 		$2.62K Buy
187
+174
+1,338% +$2.44K ﹤0.01% 3767
2025
Q1 		$203 Hold
13
– – ﹤0.01% 3664
2024
Q4 		$181 Buy
+13
New +$142 ﹤0.01% 3791

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

IFP Advisors's ARQT Position: Q2 2026 in Review

IFP Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 38% in Q2 2026, selling an estimated $2.59K and leaving 183 shares worth $4.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3822.

IFP Advisors first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.74K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • IFP Advisors held 183 shares of Arcutis Biotherapeutics worth $4.8K as of Q2 2026.
  • IFP Advisors sold 111 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.59K.
  • Arcutis Biotherapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3822 holding.
  • IFP Advisors first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • IFP Advisors's Arcutis Biotherapeutics position peaked at $8.74K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.